The Medicines Patent Pool and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries

Merck, Ridgeback Biotherapeutics and Emory University Will Not Receive Royalties for Sales of Molnupiravir Under this Agreement for as Long as COVID-19 Remains Classified as a Public Health Emergency of International Concern by the World Health Organization Collaboration Continues Merck’s Long Track Record of Making Its Medicines and Vaccines Accessible and Affordable Globally This is the First MPP Agreement to ...

Related Keywords

Japan ,United States ,Canada ,Switzerland ,Japanese ,Swiss ,Gregoryl Fenves ,Frank Clyburn ,Melissa Moody ,Philippe Duneton ,Charles Gore ,Wendy Holman ,Gelise Mccullough ,Ridgeback Biotherapeutics ,Peter Dannenbaum ,Instagram ,Linkedin ,Drug Innovation Ventures At Emory ,Emory University ,Twitter ,Statement Of Merck Co Inc ,Us National Institute Of Allergy ,Merck Co Inc ,Facebook ,Swiss Agency For Development ,Us Defense Threat Reduction Agency ,Drug Administration ,World Health Organization ,Exchange Commission ,Youtube ,Human Health ,European Medicines Agency ,Public Health Emergency Of International Concern ,Emory University Will Not Receive Royalties ,Molnupiravir Under ,Public Health Emergency ,International Concern ,Continues Merck ,Long Track Record ,Making Its Medicines ,Vaccines Accessible ,Affordable Globally ,Provide Access ,Medicines Patent Pool ,World Health ,Therapeutics Pillar ,Drug Innovation Ventures ,Threat Reduction Agency ,Emergency Use Authorization ,United Nations Backed ,Swiss Agency ,Japanese Government ,Looking Statement ,Securities Litigation Reform Act ,